These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30004617)

  • 41. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.
    Smith MP; Rupon J; Wali Y; Rimawi H; Korth-Bradley J; Smith L; Rendo P
    Haemophilia; 2020 Sep; 26(5):e232-e235. PubMed ID: 32497363
    [No Abstract]   [Full Text] [Related]  

  • 43. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.
    Mancuso ME; Fischer K; Santagostino E; Oldenburg J; Platokouki H; Königs C; Escuriola-Ettingshausen C; Rivard GE; Cid AR; Carcao M; Ljung R; Petrini P; Altisent C; Kenet G; Liesner R; Kurnik K; Auerswald G; Chambost H; Mäkipernaa A; Molinari AC; Williams M; van den Berg HM;
    Thromb Haemost; 2017 Dec; 117(12):2274-2282. PubMed ID: 29212115
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.
    van den Berg HM
    Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factor VIII recovery after a single infusion of recalibrated ReFacto in 14 severe haemophilia A patients.
    Lambert T; Guérois C; Gay V; Stieltjes N; Bertrand MA; Derlon A; Sigaud M; Hassoun A; Négrier C; Coatmelec B; Dreyfus M; Dubanchet A
    Haemophilia; 2007 Jul; 13(4):357-60. PubMed ID: 17610548
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction.
    ElAlfy MS; Tantawy AA; Ahmed MH; Abdin IA
    Haemophilia; 2000 Nov; 6(6):635-8. PubMed ID: 11122388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience.
    Mathias M; Liesner R; Hann I; Khair K
    Haemophilia; 2005 Jul; 11(4):340-5. PubMed ID: 16011585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
    Pinto P; Ghosh K; Shetty S
    Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study.
    Ewenstein BM; Gomperts ED; Pearson S; O'Banion ME
    Haemophilia; 2004 Sep; 10(5):491-8. PubMed ID: 15357776
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII.
    Hooimeijer LH; Stein-Wit MA; Voskuilen MA; Lukens MV; Meijer K; Mäkelburg AB; Tamminga RY
    Clin Appl Thromb Hemost; 2023; 29():10760296231167416. PubMed ID: 36998198
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
    Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
    Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party.
    Hay CR; Ollier W; Pepper L; Cumming A; Keeney S; Goodeve AC; Colvin BT; Hill FG; Preston FE; Peake IR
    Thromb Haemost; 1997 Feb; 77(2):234-7. PubMed ID: 9157572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors.
    van den Berg HM; Hashemi SM; Fischer K; Petrini P; Ljung R; Rafowicz A; Carcao M; Auerswald G; Kurnik K; Kenet G; Santagostino E;
    Thromb Haemost; 2016 Apr; 115(4):729-37. PubMed ID: 26632988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
    Kurnik K; Bidlingmaier C; Engl W; Chehadeh H; Reipert B; Auerswald G
    Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
    J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies.
    Messori A; Peyvandi F; Mengato D; Mannucci PM
    Haemophilia; 2017 Mar; 23(2):e87-e92. PubMed ID: 28220685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.